Detailed Research: Economic Perspectives on Honeywell International, Tabula Rasa Healthcare, El Pollo Loco, Acceleron Pharma, vTv Therapeutics, and 22nd Century Group — What Drives Growth in Today's Competitive Landscape

NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Honeywell International Inc. HON, Tabula Rasa Healthcare Inc. TRHC, El Pollo Loco Holdings, Inc. LOCO, Acceleron Pharma Inc. XLRN, vTv Therapeutics Inc. VTVT, and 22nd Century Group, Inc XXII, including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

HON DOWNLOAD: http://Fundamental-Markets.com/register/?so=HON

TRHC DOWNLOAD: http://Fundamental-Markets.com/register/?so=TRHC

LOCO DOWNLOAD: http://Fundamental-Markets.com/register/?so=LOCO

XLRN DOWNLOAD: http://Fundamental-Markets.com/register/?so=XLRN

VTVT DOWNLOAD: http://Fundamental-Markets.com/register/?so=VTVT

XXII DOWNLOAD: http://Fundamental-Markets.com/register/?so=XXII

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Honeywell International Inc. HON, Tabula Rasa Healthcare Inc. TRHC, El Pollo Loco Holdings, Inc. LOCO, Acceleron Pharma Inc. XLRN, vTv Therapeutics Inc. VTVT, and 22nd Century Group, Inc XXII on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed November 28th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

HONEYWELL INTERNATIONAL INC. (HON) REPORT OVERVIEW

Honeywell International's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Honeywell International reported revenue of $10,762.00MM vs $10,121.00MM (up 6.33%) and analysts estimated basic earnings per share $3.15 vs $1.76 (up 78.98%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Honeywell International reported revenue of $40,534.00MM vs $39,302.00MM (up 3.13%) and analysts estimated basic earnings per share $2.17 vs $6.29 (down 65.50%). Analysts expect earnings to be released on January 25th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $1.85. The estimated EPS forecast for the next fiscal year is $8.03 and is expected to report on January 25th, 2019.

To read the full Honeywell International Inc. (HON) report, download it here: http://Fundamental-Markets.com/register/?so=HON

-----------------------------------------

TABULA RASA HEALTHCARE INC. (TRHC) REPORT OVERVIEW

Tabula Rasa Healthcare's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Tabula Rasa Healthcare reported revenue of $54.42MM vs $32.73MM (up 66.26%) and analysts estimated basic earnings per share $0.54 vs $0.37 (up 45.95%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Tabula Rasa Healthcare reported revenue of $134.55MM vs $94.06MM (up 43.04%) and analysts estimated basic earnings per share $0.85 vs -$0.51. Analysts expect earnings to be released on March 11th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.06. The estimated EPS forecast for the next fiscal year is $0.63 and is expected to report on March 11th, 2019.

To read the full Tabula Rasa Healthcare Inc. (TRHC) report, download it here: http://Fundamental-Markets.com/register/?so=TRHC

-----------------------------------------

EL POLLO LOCO HOLDINGS, INC. (LOCO) REPORT OVERVIEW

El Pollo Loco's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, El Pollo Loco reported revenue of $112.18MM vs $101.16MM (up 10.90%) and analysts estimated basic earnings per share $0.18 vs -$0.11. For the twelve months ended December 31st, 2017 vs December 31st, 2016, El Pollo Loco reported revenue of $401.70MM vs $380.12MM (up 5.68%) and analysts estimated basic earnings per share $0.22 vs $0.48 (down 54.17%). Analysts expect earnings to be released on March 14th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.11. The estimated EPS forecast for the next fiscal year is $0.78 and is expected to report on March 14th, 2019.

To read the full El Pollo Loco Holdings, Inc. (LOCO) report, download it here: http://Fundamental-Markets.com/register/?so=LOCO

-----------------------------------------

ACCELERON PHARMA INC. (XLRN) REPORT OVERVIEW

Acceleron Pharma's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Acceleron Pharma reported revenue of $3.26MM vs $3.01MM (up 8.10%) and basic earnings per share -$0.63 vs -$0.65. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Acceleron Pharma reported revenue of $13.48MM vs $27.77MM (down 51.46%) and analysts estimated basic earnings per share -$2.68 vs -$1.52. Analysts expect earnings to be released on February 26th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.62. The estimated EPS forecast for the next fiscal year is -$2.05 and is expected to report on February 26th, 2019.

To read the full Acceleron Pharma Inc. (XLRN) report, download it here: http://Fundamental-Markets.com/register/?so=XLRN

-----------------------------------------

VTV THERAPEUTICS INC. (VTVT) REPORT OVERVIEW

vTv Therapeutics' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, vTv Therapeutics reported revenue of $3.38MM vs $0.02MM (up 22,400.00%) and analysts estimated basic earnings per share -$0.06 vs -$0.38. For the twelve months ended December 31st, 2017 vs December 31st, 2016, vTv Therapeutics reported revenue of $0.29MM vs $0.63MM (down 54.10%) and analysts estimated basic earnings per share -$1.67 vs -$1.71. Analysts expect earnings to be released on February 26th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.44. The estimated EPS forecast for the next fiscal year is -$0.67 and is expected to report on February 26th, 2019.

To read the full vTv Therapeutics Inc. (VTVT) report, download it here: http://Fundamental-Markets.com/register/?so=VTVT

-----------------------------------------

22ND CENTURY GROUP, INC (XXII) REPORT OVERVIEW

22nd Century Group's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, 22nd Century Group reported revenue of $6.26MM vs $4.53MM (up 38.17%) and analysts estimated basic earnings per share $0.05 vs -$0.03. For the twelve months ended December 31st, 2017 vs December 31st, 2016, 22nd Century Group reported revenue of $16.60MM vs $12.28MM (up 35.18%) and analysts estimated basic earnings per share -$0.13 vs -$0.15. Analysts expect earnings to be released on February 6th, 2019. The report will be for the fiscal period ending December 31st, 2018.

To read the full 22nd Century Group, Inc (XXII) report, download it here: http://Fundamental-Markets.com/register/?so=XXII

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:

Andrew Duffie, Media Department

Office: +1 667-401-0010

E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.